Navigation Links
goBalto, Inc. expands Tracker 2.0's analytics and submissions features
Date:10/29/2013

SAN FRANCISCO, Oct. 29, 2013 /PRNewswire/ -- goBalto, Inc. announced today that the latest release of its signature product, Tracker 2.0, is now available.

With its 9th release, Tracker adds critical path reporting and a submissions manager. Now, clinical study managers can view the percentage of sites activated and the milestones blocking study startup completion, without having to wait for status reports that normally take up to a week.

The new critical path reports show all the documents and submissions along the critical path to key company milestones, and the overall status of all milestones for a study. There's a version that's suitable for country managers and another for printing and sending to sponsors.

The submissions manager allows specialists to plan and track documents to be included in an ethics or regulatory committee submission. A submission status report shows which study country and site documents are complete for a submission, and which ones are still in progress.

Jae Chung, founding CEO of goBalto, stated, "The life sciences industry is continually seeking ways to be more efficient in how they get their clinical studies started. Our new release focuses on innovation, going to the heart of how we can best help our partners quickly identify and resolve bottlenecks. In this critical phase of the process, our customers can't afford to wait multiple days for status or wonder how ready they are to complete a submission."

About goBalto

goBalto develops next-generation solutions that simplify how clinical trials are started in the pharmaceutical, biotechnology, and medical device industries. Our flagship product, Tracker, is a purpose-built software-as-a-service clinical research platform. It enables clinical trial sponsors and research organizations to track milestones on the critical path, and provides document workflow management capabilities in a transparent, regulatory-compliant, and user-friendly way. Founded in 2008 in Silicon Valley by biotechnology industry veteran Jae Chung, goBalto is backed by leading health technology investors. For more information, visit www.gobalto.com.

CONTACT: Maria Breaux, 415 994 5040, mbreaux@gobalto.com

Video with caption: "goBalto CEO and founder Jae Chung introduces the latest release of Tracker 2.0. With this release, Tracker adds critical path reporting and a submissions manager. Now, clinical study managers can view the percentage of sites activated and milestones blocking study startup completion, without having to wait for status reports that normally take up to a week. The submissions manager allows study startup specialists to specify country and site documents to include and track in a submission package." Video available at: http://youtu.be/JqvCJ2dehD0


'/>"/>
SOURCE goBalto
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Private Hospital Group in Spain Expands Radiotherapy Capabilities with Countrys First Elekta Versa HD System
2. Predilytics Secures Additional Funding and Expands Board of Directors
3. Indivumed Sells Inostics, the plasma-DNA Company, to Sysmex and Expands its Clinical Research Service and Patient Diagnostics Business
4. Trovagene Expands NPM Patent Coverage
5. Lupin Expands US Pediatric Brands Portfolio
6. SeraCare Life Sciences Expands R&D Facilities
7. Sam Solakyan Successfully Expands Vital Imaging Across California
8. American Cancer Society Expands Efforts to Reduce Burden of Cancer in Underserved Communities
9. SottoPelle expands its East Coast Presence
10. UBM Medica US Expands Network to Include Pharmacology and Psychopharmacology
11. Kush Bottles Expands Free and Same Day Delivery to Encompass More of Washington State
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... SAN DIEGO , Feb. 8, 2016 /PRNewswire/--  ... have announced that advanced tissue-engineering services are now ... using a groundbreaking new three-dimensional (3D) bioprinting approach ... Regenova® 3D Bio Printer , a state-of-the-art robotic ... Applications has created a powerful pay-for-service bio-printing model ...
(Date:2/8/2016)... Feb. 8, 2016  Avista Pharma Solutions ("Avista Pharma") ... as Chief Financial Officer (CFO). Mr. Setzer is a ... experience in various roles within growing technology and life ... as the Executive Director of Finance at INC Research, ... Raleigh, NC . Previously, Mr. Setzer served as ...
(Date:2/8/2016)... 8, 2016 Velano Vascular, a medical technology ... patients and their practitioners, announced today that the company ... will use the proceeds from this financing, an extension ... January 2015, to support the development and commercialization of ... populations. Philadelphia , and ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Steve Helwig & Associates Insurance & Financial, serving the ... has teamed up with Citizens Opposed to Domestic Abuse in support of its efforts ... all those victimized by the fear of violence in their own homes, donations may ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... and relationship-marketing firm, announced today that nominations will be accepted February 8, ... West Awards. , Awards include the Information Security Executive® of the ...
(Date:2/8/2016)... ... , ... Discover the Rocky Mountain region’s longest running and impressive garden and ... also get to see the most incredible gardens and home improvement experts that attend ... Colorado Convention Center - 700 14th St. Denver CO, is an exciting event that ...
(Date:2/8/2016)... Las Vegas, Nevada (PRWEB) , ... February 08, ... ... Co-Founder at RowdMap, Inc., will be speaking on how healthcare companies can use ... project costs, manage the health of a population and intervene and capture the ...
(Date:2/7/2016)... , ... February 07, 2016 , ... ... with the latest techniques and the most minimally invasive approaches. , Women who ... particularly after menopause. Other risk factors include surgery to the pelvic floor, connective ...
Breaking Medicine News(10 mins):